Organic Process Research & Development
Technical Note
(4) Vogel, J. U.; Cinatl, J.; Dauletbaev, N.; Buxbaum, S.; Treusch, G.;
Cinatl, J., Jr.; Gerein, V.; Doerr, H. W. Med. Microbiol. Immunol. 2005,
194, 55−59.
L), and CoCl2 (10.56 g, 0.081 mol) at 0−5 °C over a period of
5 min. Thereafter, the temperature was raised to 20−30 °C, and
the reaction mixture was stirred for 10 min. The progress of the
reaction was monitored by HPLC. After completion, the
reaction was quenched by addition of 0.21 L of methanol, and
the reaction mixture was stirred for an additional 20 min at
room temperature. The TFA and DMF were removed in vacuo,
and ethyl acetate (50 L) was added to the resulting oil. The
mixture was cooled to 0 °C obtaining a white solid overnight.
The crude precipitate was dissolved in 20 L of warm water (40
°C). The obtained solution was further diluted with 60 L of
acetone. After cooling in an ice−water bath for about 2 h, the
white crystalline material formed was collected, washed with
the solvent (3.0 L, acetone/water, 2/1), and dried under
vacuum affording S-acetyl-L-glutathione (5.20 kg, yield 91.5%).
Chromatographic purity: 99.7% (by HPLC). mp 202−203
°C. [α]D20 = −16.5 (1.0 water). 1H NMR (400 Hz, DMSO-d6):
δ (ppm) 8.71 (t, J = 6.0, 1H), 8.47 (d, J = 8.8, 1H), 4.39 (m,
1H), 3.68 (d, J = 6.0, 2H), 3.36 (m, 2H), 3.28 (t, J = 6.4, 2H),
2.93 (m, 1H), 2.31 (s, 3H), 2.28 (m, 2H), 1.90 (m, 1H), 1.83
(m, 1H). 13C NMR (400 Hz, DMSO-d6): δ (ppm) 196.38,
172.24, 171.35, 170.74, 170.63, 53.48, 52.33, 41.69, 31.82,
31.00, 30.93, 27.21. IR (KBr, cm−1): 3355, 3059, 2956, 2729,
1701, 1677, 2648, 1514, 1432, 1353, 1231, 1132, 963, 636.
Recycling Process for TFA. Acetyl chloride (1.7 kg) was
slowly added to fraction 1 (7 kg) at room temperature.
Thereafter, the reaction mixture was stirred for 1 h at room
temperature. An atmospheric distillation process was used to
separate TFA from the Fraction 1. We removed the front cut
fraction (<70 °C) and collected the fraction of 70−75 °C (6.3
kg, purity 99.2%, area %).
(5) (a) Murata, Y.; Shimamura, T.; Hamuro, J. Int. Immunol. 2002,
14, 201−212. (b) Palamara, A. T.; Garaci, E.; Rotilio, G.; Ciriolo, M.
R.; Casablanca, A.; Fraternale, A.; Rossi, L.; Schiavano, G. F.;
Chiarantlni, L.; Magnani, M. Retroviruses. 1996, 12, 1373−1381.
(c) Zampagni, M.; Wright, D.; Cascella, R.; D’Adamio, G.; Casamenti,
F.; Evangelisti, E.; Cardona, F.; Goti, A.; Nacmias, B.; Sorbi, S.; Liguri,
G.; Cecchi, C. Free Radical Biol. Med. 2012, 52, 1362−1371. (d) Shen,
B.; Bazin, C.; Ann, M. J. Pept. Sci. 2013, 19, 263−267.
(6) Okun, J. G.; Sauer, S.; Bahr, S.; Lenhartz, H.; Mayatepek, E. J.
̈
Inherited Metab. Dis. 2004, 27, 783−786.
(7) (a) Galzigna, L.; Rizzoli, V.; Schiapelli, P.; Moretto, C.;
Bernareggi, A. Enzyme Protein 1995, 48, 98−104. (b) Cacciatore, I.;
Cornacchia, C.; Pinnen, F.; Mollica, A.; Stefano, A. D. Molecules 2010,
15, 1242−1264.
(8) Stadtman, E. R. J. Biol. Chem. 1952, 196, 535−546.
(9) Wieland, T.; Bokelmann, E. Angew. Chem. 1952, 64, 59.
(10) Kielley, W. W.; Bradley, L. B. J. Biol. Chem. 1954, 206, 327−333.
(11) Lauro, G. Patent WO 9200320, 1992.
(12) (a) Gorog, S. J. Pharm. Biomed. Anal. 2008, 48, 247−253.
̈
̈
(b) Gorog, S. Trends Anal. Chem. 2006, 25, 755−757.
̈
̈
(13) (a) Sharma, S. D.; Bastos, M.; Yang, W. US 20100035821, 2010.
(b) Conway, P. A.; Devine, K.; Paradisi, F. Tetrahedron 2009, 65,
2935−2938. (c) El-Koussi, N. A. Bull. Pharm. Sci. Assiut Univ. 2009,
32, 225−240.
(14) (a) Meshram, H. M.; Reddy, G. S.; Hima, B. K.; Yadav, J. S.
Synlett. 1998, 8, 877−878. (b) Pasha, M. A.; Reddy, M. B. M.; Manjula,
K. Eur. J. Chem. 2010, 1, 385−387. (c) Bandgar, B. P.; More, P. E.;
Kamble, V. T.; Sawant, S. S. Aust. J. Chem. 2008, 61, 1006−1010.
(15) Ahmad, S.; Iqbal, J. Tetrahedron Lett. 1986, 27, 3791−3794.
(16) Ghosh, R.; Maiti, S.; Chakraborty, A. Tetrahedron Lett. 2004, 45,
6775−6778.
(17) (a) Tamilselvan, P.; Basavaraju, B. Y.; Murugesan, R.;
Sampathkumar, E. Catal. Commun. 2008, 10, 300−303. (b) Velusamy,
S.; Borpuzari, S.; Punniyamurthy, T. Tetrahedron 2005, 61, 2011−
2015. (c) Iqbal, J.; Srivastava, R. R. Tetrahedron 1991, 47, 3155−3170.
(d) Iqbal, J.; Khan, M. A.; Nayyar, K. N. Tetrahedron Lett. 1991, 32,
5179−5182. (e) Iqbal, J.; Srivastava, R. R. J. Org. Chem. 1992, 57,
2001−2007.
ASSOCIATED CONTENT
■
S
* Supporting Information
1H, 13C, IR spectrum, and HPLC chromatogram of S-acetyl-L-
glutathione. GC chromatogram of recovered TFA. The
Supporting Information is available free of charge on the
AUTHOR INFORMATION
■
Corresponding Author
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
We thank our college at foundation and analysis for their
contributions to the project.
REFERENCES
■
(1) (a) Dringen, R. Prog. Neurobiol. 2000, 62, 649−671. (b) Droge,
W.; Schulze-Osthoff, K.; Mihm, S.; Galter, D.; Schenk, H.; Eck, H. P.;
̈
Roth, S.; Gmunder, H. FASEB J. 1994, 8, 1131−1138.
̈
(2) (a) Droge, W.; Eck, H. P.; Mihm, S. Immunol. Today. 1992, 13,
̈
211−214. (b) Fraternalea, A.; Paolettia, M. F.; Casabiancaa, A.;
Orlandi, C.; Schiavano, G. F.; Chiarantini, L.; Clayette, P.; Oiry, J.;
Vogel, J. U.; Cinatl, J., Jr.; Magnani, M. Antiviral Res. 2008, 77, 120−
127. (c) Donnerstag, B.; Ohlenschlager, G.; Cinatl, J.; Amrani, M.;
Hofmann, D.; Flindt, S.; Treusch, G.; Trager, L. Cancer Lett. 1996,
̈
110, 63−70.
(3) Wendel, A.; Cikryt, P. FEBS Lett. 1980, 120, 209−211.
D
Org. Process Res. Dev. XXXX, XXX, XXX−XXX